Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
Por:
Guardo AC, Gómez CE, Diaz de Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M and RISVAC02boost study
Publicada:
24 oct 2017
Ahead of Print:
24 oct 2017
Resumen:
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost.
Open Access
|